Iron accumulation and neuroinflammation are pathological conditions found in several
neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease …

Parkinson's disease (PD) is a chronic neurodegenerative condition affecting more than 1%
of people over 65 years old. It is characterized by the preferential degeneration of …

Background Development of reliable and accurate imaging biomarkers of dopaminergic cell
neurodegeneration is necessary to facilitate therapeutic drug trials in Parkinson's disease …

Background More than 200 years after James Parkinsondescribed a clinical syndrome
based on his astute observations, Parkinson's disease (PD) has evolved into a complex …

In Parkinson's disease, there is a progressive reduction in striatal dopaminergic function,
and loss of neuromelanin-containing dopaminergic neurons and increased iron deposition …

About 60 years ago, the discovery of a deficiency of dopamine in the nigro-striatal system
led to a variety of symptomatic therapeutic strategies to supplement dopamine and to …

Parkinson's disease (PD) is a neurodegenerative synucleinopathy characterized by the
degeneration of neuromelanin (NM)-containing dopaminergic neurons and deposition of …

Alzheimer's disease (AD) is a debilitating brain disorder that afflicts millions worldwide with
no effective treatment. Currently, AD progression has primarily been characterized by …

Parkinson's disease (PD) is characterized by a progressive loss of dopaminergic neurons.
Exercise has been reported to slow the clinical progression of PD. We evaluated the …

Ferroptosis, a newly identified iron-dependent form of cell death, has recently been
implicated in the pathogenesis of Parkinson's disease (PD). Dl-3-n-butylphthalide (NBP) …